Hepcortespenlisimut-L

Drug Profile

Hepcortespenlisimut-L

Alternative Names: Hepko-V5; V-5; V-5 Immunitor

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunitor
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • No development reported Hepatitis B; Hepatitis C; Tuberculosis

Most Recent Events

  • 13 Apr 2017 Hepcortespenlisimut-L licensed to Key Capital Group
  • 13 Apr 2017 Efficacy and pharmacodynamics data from a phase II trial in Hepatocellular carcinoma released by Immunitor
  • 01 Oct 2014 No development reported - Phase-II for Hepatitis B and Hepatitis C in Mongolia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top